Relationships between histomorphometric features of bone formation and bone cell characteristics in vitro in renal osteodystrophy.
To determine whether abnormal bone cell recruitment or differentiation may be involved in the development of aplastic bone lesion in renal osteodystrophy we have compared histomorphometric parameters of bone formation and in vitro behavior of osteoblastic cells isolated from the trabecular bone surfaces in 37 dialysis patients with osteitis fibrosa, normal bone formation rate, or aplastic bone lesion. The bone cell responses to human PTH-(1-34) (20 nmol/L), as evaluated by intracellular cAMP production, and to 1,25-dihydroxyvitamin D (10 nmol/L), as assessed by osteocalcin synthesis, were not different from normal in patients with low, normal, or high bone formation rates. Osteoblastic cells isolated from patients with a high bone formation rate and markedly elevated serum iPTH and osteocalcin values had a higher than normal DNA replication in primary culture. The peak of [3H]thymidine incorporation, the maximal DNA synthesis, and the area under the growth curve were 4.4- to 6.3-fold increased in osteitis fibrosa compared to those in normal bone cells obtained from age-matched individuals. By contrast, [3H]thymidine incorporation in bone cells from aplastic patients was about 25% of normal and only 5% of the value in osteitis fibrosa. The decreased DNA replication of cultured bone cells in aplastic patients was unrelated to trabecular bone aluminum staining, but was associated with low serum immunoreactive PTH values compared to those in other groups of patients. These results show that high bone formation in uremic osteoitis fibrosa is associated with higher than normal [3H]thymidine incorporation in bone cells in vitro, whereas low bone formation in aplastic patients results from lower than normal DNA replication and suggest that the defective osteoblastic recruitment in aplastic patients may be related to factors other than aluminum, including inappropriate PTH secretion.
Marie
P J
PJ
INSERM Unité 18, Hôpital Lariboisière, Paris, France.
Lomri
A
A
de Vernejoul
M C
MC
Morieux
C
C
Graulet
A M
AM
Guéris
J
J
Llach
F
F
D001706:Biopsy; D001846:Bone Development; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D002478:Cells, Cultured; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000473:pathology / Q000503:physiopathology*; D000242:Cyclic AMP / Q000378:metabolism; D004261:DNA Replication; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000096:biosynthesis / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood / Q000494:pharmacology; D012016:Reference Values; D013936:Thymidine / Q000378:metabolism; D014511:Uremia / Q000503:physiopathology
D010281:Parathyroid Hormone; D015675:Osteocalcin; D000242:Cyclic AMP; D013936:Thymidine